SCHEMBL1556091

SCHEMBL1556091

Brc1ccc(-n2nccn2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
AKR1C3 P42330 1/20 0.37
MAPT P10636 2/20 0.37
NPC1 O15118 2/20 0.36
HCRTR1 O43613 1/20 0.35
ADRA2A P08913 2/20 0.34
ADRA2B P18089 2/20 0.34
ADRA2C P18825 2/20 0.34
PLAU P00749 1/20 0.34
GBA1 P04062 1/20 0.34
DPP4 P27487 1/20 0.34
G6PD P11413 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29972696 0.75 GRIN2D (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL26353189 0.75 GRIN2D (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29696447 0.74 GRIN2D (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27163480 0.74 GRIN2D (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30180868 0.74 GRIN2D (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30047391 0.74 ADORA1 (0.32) MAPTGAA
SCHEMBL2067481 0.72 LMNA (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23529802 0.71 POLB (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15081260 0.70 KDM4E (0.50) ALDH1A1KDM4EHCRTR1
SCHEMBL11356194 0.70 GRIN2D (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
WO-2024129634-A1 RBM39 SULFONAMIDE INHIBITORS RECURSION PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist RAQUALIA PHARMA INC. (JP) 2023-10-31 US disclosed
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist RAQUALIA PHARMA INC. (JP) 2023-10-31 US disclosed
US-20210121449-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2021-04-29 US disclosed
US-20210078975-A1 FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2021-03-18 US disclosed
US-20200078345-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2020-03-12 US disclosed
US-20180344716-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2018-12-06 US disclosed
US-20170333414-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2017-11-23 US disclosed
US-20170049763-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2017-02-23 US disclosed
EP-1699784-B1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A PHARM CO LTD (KR) 2011-06-29 EP disclosed
EP-2305657-A2 Oxazolidinone derivatives Dong-A Pharmaceutical Co., Ltd. (KR) 2011-04-06 EP disclosed
CN-101982468-A Novel oxazolidinone derivatives and pharmaceutical compositions comprising the derivatives DONG A PHARM CO LTD 2011-03-02 CN disclosed
US-7816379-B2 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate DONG-A PHARM. CO., LTD. (KR) 2010-10-19 US disclosed
US-20090192197-A1 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate DONG-A PHARM. CO., LTD. (KR) 2009-07-30 US disclosed
EP-1699784-A4 NOVEL OXAZOLIDINONE DERIVATIVES DONG A PHARM CO LTD (KR) 2008-09-03 EP disclosed
US-20070155798-A1 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate DONG-A PHARM. CO., LTD. 2007-07-05 US disclosed
CN-1894242-A Novel oxazolidinone derivatives DONG A PHARM CO LTD (KR) 2007-01-10 CN disclosed
EP-1699784-A1 NOVEL OXAZOLIDINONE DERIVATIVES Dong-A Pharmaceutical Co., Ltd. (KR) 2006-09-13 EP disclosed
WO-2005058886-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG-A PHARM.CO.,LTD. (KR) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170049763-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI GRIN2D 3970/4885GRIN3B 3557/4885GRIN1 3387/4885
US-20210121449-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI GRIN2D 3970/4885GRIN3B 3557/4885GRIN1 3387/4885
US-20070155798-A1 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate ALPI, SI, TST GRIN2D 4265/4885GRIN3B 4327/4885GRIN1 3586/4885
US-20200078345-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI GRIN2D 3970/4885GRIN3B 3557/4885GRIN1 3387/4885
US-20210078975-A1 FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH GRIN2D 2062/4885GRIN3B 1181/4885GRIN1 961/4885
US-20090192197-A1 Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate ALPI, TPI1, SI GRIN2D 3743/4885GRIN3B 3460/4885GRIN1 2761/4885
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist CRHR2, CRHR1, CRH GRIN2D 2062/4885GRIN3B 1181/4885GRIN1 961/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 GRIN2D 4296/4885GRIN3B 4221/4885GRIN1 1424/4885
US-20170333414-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI GRIN2D 3970/4885GRIN3B 3557/4885GRIN1 3387/4885
US-20180344716-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI GRIN2D 3970/4885GRIN3B 3557/4885GRIN1 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.